Supplementary Figure 2 from Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure 2. Combination therapy with macitentan plus TMZ eradicates experimental glioblastomas.
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361919163